Kemal Tekeşin

Kemal Tekeşin

Auto-generated profile, based on publicly available information

Kemal Tekeşin

Department of General Surgery, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Medicine
Verified
Journal Article
Open access
İKİlyas Kudaş
İlyas Kudaş
FBFatih Basak
Fatih Basak
YÇYahya Kemal Çalişkan
Yahya Kemal Çalişkan
HTHüsna Tosun
Hüsna Tosun
AAAylin Acar
Aylin Acar
KTKemal Tekeşin
Kemal Tekeşin
Gallbladder diseases, including chronic cholecystitis and cholesterolosis, impose a significant burden on global health. Monitoring their evolving trends is vital to refine diagnostic strategies and improve clinical outcomes. This study evaluates a decade of gallbladder pathology data to identify epidemiological shifts and associated risk factors. This retrospective study analyzed 6665 cholecystectomy specimens from January 2014 to December 2023. Diagnoses included chronic and acute cholecystitis, cholesterolosis, metaplasia, dysplasia, and adenocarcinoma. Annual trends, demographic patterns, and risk factor correlations were examined using advanced statistical analyses, including multivariable logistic regression. Chronic cholecystitis remained the most common diagnosis (87.92%), showing a stable incidence and strong female predominance (4115:1745; P < .001). Cholesterolosis (24.07%) exhibited a rising trend, peaking in 2022, linked to dietary and metabolic changes. Notably, premalignant lesions such as metaplasia (12.54%) and dysplasia (3.11%) increased significantly, with dysplasia peaking in 2022–2023. Adenocarcinoma was rare (0.33%) but strongly correlated with dysplasia (r = 0.186, P < .001). Logistic regression analysis identified age and intestinal metaplasia as independent predictors of dysplasia. For adenocarcinoma, high-grade dysplasia (odds ratio [OR] = 308.9), polyps (OR = 2.9), and intestinal metaplasia (OR = 3.8) emerged as significant risk factors, while chronic cholecystitis (OR = 0.18) and gallstones (OR = 0.31) were independently associated with a reduced risk. The rise in premalignant gallbladder conditions, particularly dysplasia, underscores the importance of routine histopathological examinations following cholecystectomy. Targeted monitoring for high-risk patients and standardized early detection strategies are critical. Future studies should aim to validate these findings in larger, prospective cohorts and investigate the underlying mechanisms—both protective and promotive—by which various histopathological and clinical factors may influence the progression from benign to malignant gallbladder lesions.

27 February 2025 in Turkish Journal of Surgery
Verified
Journal Article
Open access
OEOlgun Erdem
Olgun Erdem
TCTolga Canbak
Tolga Canbak
MBMehmet Erman Bacaksız
Mehmet Erman Bacaksız
SASuat Aktaş
Suat Aktaş
KTKemal Tekeşin
Kemal Tekeşin
FBFatih Basak
Fatih Basak
Gastric cancer (GC), with a five-year survival rate of approximately 20%, frequently displays aggressive behavior when HER-2 is overexpressed. While trastuzumab, a monoclonal antibody against human epidermal growth factor receptor-2 (HER-2), has improved outcomes in advanced GC, its effect in resectable disease is less studied. This retrospective study included patients who underwent total gastrectomy with D2 lymph node dissection between 2016 and 2021. Among 180 patients, HER-2 status was determined for 97 cases. Of these, 20 HER-2 positive patients received trastuzumab-containing therapies. A control group of 40 HER-2 negative patients was randomly selected. Overall survival (OS) was compared between groups. Univariate and multivariate analyses were used to identify prognostic factors. Sixty patients with a median follow-up of 29.5 months were analyzed. HER-2 positivity was associated with significantly improved OS (p=0.038). Univariate analyses revealed that HER-2 positivity (p=0.047), younger age (p=0.001), advanced tumor stage (p<0.001), and larger tumor size (p=0.010) were significantly related to OS. In the multivariate model, advanced tumor stage [hazard ratio (HR)=3.634, p=0.001] and younger age (HR=0.213, p<0.001) remained independent predictors of worse survival, while HER-2 positivity and tumor size lost their significance. Tumor subtype and location did not significantly influence OS. The findings suggest that trastuzumab-containing treatment strategies can markedly improve survival in resectable HER-2 positive GC. Routine assessment of HER-2 status and integration of targeted therapies may enhance patient outcomes. In addition, advanced stage and younger age emerged as key prognostic factors.

12 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
KTKemal Tekeşi̇n
Kemal Tekeşi̇n
TCTolga Canbak
Tolga Canbak
AAAyli̇n Acar
Ayli̇n Acar
FBFatih Basak
Fatih Basak
HKHasan Kumru
Hasan Kumru
OEOlgun Erdem
Olgun Erdem
Background/aim: Early risk stratification is required in cases of acute biliary pancreatitis (ABP). Traditional scoring systems such as Ranson’s criteria are complex and often delay treatment. D-dimer, a basic marker of systemic inflammation and coagulation, has shown promise as a prognostic tool. The present study investigates whether the predictive accuracy of serial serum D-dimer measurements is superior to that of the Ranson and BISAP scoring systems for moderate-to-severe ABP. Materials and methods: Included in this single-center prospective observational study were 264 patients diagnosed with ABP between July 2022 and July 2025 whose collected data were analyzed. The participants were categorized as mild, moderate, or severe based on the current Revised Atlanta Classification (2012), and D-dimer levels were measured at admission (H0), 24 h (H24), and 48 h (H48), along with their BISAP scores to allow a comparative analysis. Results: Mean D-dimer levels increased significantly with disease severity at all timepoints (p < 0.001). ROC analysis identified the D-dimer level at H48 to have the highest discriminative value for predicting moderate-to-severe ABP (AUC: 0.812; 95% CI: 0.758– 0.866). The H24 and H0 D-dimer levels also performed well (AUCs: 0.728 and 0.719, respectively). In comparison, the Ranson (H48 AUC: 0.741) and BISAP scores (H24 AUC: 0.755) yielded lower predictive accuracy – the H48 D-dimer AUC being statistically superior to both (p < 0.05). Conclusion: Serum D-dimer levels are significantly associated with ABP severity and show promise as a practical, accessible, and cost-effective adjunctive biomarker for early risk assessment. Serial measurements, especially at 48 h, offer superior diagnostic accuracy compared to Ranson and BISAP scoring alone. The clinical measurement of D-dimer levels at 48 h can thus be considered an accessible and timely triage approach. Multicenter prospective validation studies are needed to confirm the diagnostic thresholds and to assess clinical integration.

1 December 2018 in Medical Journal of Bakırkoy
Verified
Journal Article
Closed access
SBSavaş Bayrak
Savaş Bayrak
MGMehmet Emin Güneş
Mehmet Emin Güneş
KTKemal Tekeşin
Kemal Tekeşin
EAEmre Akar
Emre Akar
DTDeniz Tural
Deniz Tural

10 November 2025 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
TCTolga Canbak
Tolga Canbak
MGMert Gedik
Mert Gedik
KTKemal Tekeşin
Kemal Tekeşin
AAAbdulbaki Ağaçkıran
Abdulbaki Ağaçkıran
AAAylin Acar
Aylin Acar
FBFatih Basak
Fatih Basak

25 March 2026 in BMC Surgery
Verified
Journal Article
Open access
PDF file
OEOlgun Erdem
Olgun Erdem
AAAylin Acar
Aylin Acar
TCTolga Canbak
Tolga Canbak
FBFatih Basak
Fatih Basak
KTKemal Tekeşin
Kemal Tekeşin
YÇYahya Kemal Çalışkan
Yahya Kemal Çalışkan
Turkey is undergoing a significant demographic transition characterized by an increasing elderly population and a declining youth demographic. This study a